These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 17105932

  • 1. Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism.
    Samantaray S, Ray SK, Ali SF, Banik NL.
    Ann N Y Acad Sci; 2006 Aug; 1074():349-56. PubMed ID: 17105932
    [Abstract] [Full Text] [Related]

  • 2. Extranigral neurodegeneration in Parkinson's disease.
    Samantaray S, Butler JT, Ray SK, Banik NL.
    Ann N Y Acad Sci; 2008 Oct; 1139():331-6. PubMed ID: 18991878
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice.
    Samantaray S, Knaryan VH, Shields DC, Cox AA, Haque A, Banik NL.
    Mol Neurobiol; 2015 Oct; 52(2):1054-66. PubMed ID: 26108182
    [Abstract] [Full Text] [Related]

  • 8. Cell-Permeable Calpain Inhibitor SJA6017 Provides Functional Protection to Spinal Motoneurons Exposed to MPP.
    Samantaray S, Knaryan VH, M Del Re A, Woodward JJ, Shields DC, Azuma M, Inoue J, Ray SK, Banik NL.
    Neurotox Res; 2020 Oct; 38(3):640-649. PubMed ID: 32761446
    [Abstract] [Full Text] [Related]

  • 9. Calpain as a potential therapeutic target in Parkinson's disease.
    Samantaray S, Ray SK, Banik NL.
    CNS Neurol Disord Drug Targets; 2008 Jun; 7(3):305-12. PubMed ID: 18673214
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration.
    Kieran D, Greensmith L.
    Neuroscience; 2004 Jun 19; 125(2):427-39. PubMed ID: 15062985
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease.
    Duan W, Mattson MP.
    J Neurosci Res; 1999 Jul 15; 57(2):195-206. PubMed ID: 10398297
    [Abstract] [Full Text] [Related]

  • 16. Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease.
    Corona JC, Gimenez-Cassina A, Lim F, Díaz-Nido J.
    J Neurosci Res; 2010 Jul 15; 88(9):1943-50. PubMed ID: 20143419
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis.
    Guyton MK, Wingrave JM, Yallapragada AV, Wilford GG, Sribnick EA, Matzelle DD, Tyor WR, Ray SK, Banik NL.
    J Neurosci Res; 2005 Jul 01; 81(1):53-61. PubMed ID: 15952172
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.